Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Breast01
NCT06926868Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 28
01
Overview
A Phase 3 trial of izalontamab brengitecan in breast cancer, sponsored by Bristol Myers Squibb. Started Sep 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06926868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926868.